Hongyan Wu

Dr. Hongyan Wu

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
JLJiajun Liu
Jiajun Liu
YFYihui Fu
Yihui Fu
PLPengpeng Liang
Pengpeng Liang
ZSZhangxiao Song
Zhangxiao Song
YLYue Li
Yue Li
HWHongyan Wu
Hongyan Wu
Triglyceride glucose index (TyG) serves as an effective parameter for assessing metabolic status. However, it remains uncertain whether TyG and other metabolic parameters can predict clinical outcomes in people with metabolic syndrome (MetS). We investigated the association of TyG, triglyceride glucose-waist to height ratio (TyG-WHtR), and metabolic score for insulin resistance (METS-IR) with all-cause and cardiovascular mortality in the MetS cohort and determined whether this association changes with age. Participants enrolled in the National Health and Nutrition Examination Survey (NHANES) between 2001 and 2018 were selected and categorized into two groups: younger individuals (age < 65 years) and older individuals (age ≥ 65 years). Three new metabolic indices of TyG, TyG-WHtR, and METS-IR were constructed. The weighted Cox proportional hazards model and restricted cubic spline (RCS) models were employed to evaluate the relation between three indices and mortality outcomes. The time-dependent receiver operating characteristic (ROC) curve assessed the ability of different indices to predict mortality. Sensitivity analysis was conducted to evaluate the robustness and reliability of the findings. The study comprised a total of 8271 participants, including 5456 younger participants and 2815 older participants, and 1407 deaths were observed over a median follow-up period of 8.3 years. Compared with the first quartile (Q1), the fourth quartile’s (Q4) TyG, TyG-WHtR, and METS-IR were linked to an increased risk of all-cause mortality (HR 1.63, 95% CI 1.12–2.39; HR 2.78, 95% CI 1.68–4.61; HR 1.36, 95% CI 1.12–2.02, respectively) and cardiovascular mortality (HR 2.04, 95% CI 1.15–4.90; HR 4.99, 95% CI 1.76–14.11; HR 2.69, 95% CI 1.89–8.15, respectively) in the younger group but not in the older group. The RCS results showed no significant non-linear associations between TyG, TyG-WHtR, METS-IR, and all-cause (P = 0.082; P = 0.712; P = 0.062, respectively) or cardiovascular mortality (P = 0.176; P = 0.793; P = 0.482, respectively) in the older age group. TyG-WHtR demonstrated the highest area under the curve for predicting 3-year mortality in the younger age group, with values of 0.653 for all-cause mortality and 0.688 for cardiovascular mortality. Our results highlight the predictive value of TyG, TyG-WHtR, and METS-IR in the MetS population, providing new evidence for medical practice and public health. A total of 8271 younger (age < 65 years) and older (age ≥ 65 years) participants were enrolled in the study, with a median follow-up of 100 months. Weighted COX regression results (left), restricted cubic spline results (upper right), and time-dependent (cut-off value of 36 months) receiver operating characteristic curve results (lower right). TyG Triglyceride glucose index; WHtR Triglyceride glucose-waist to height ratio; METS-IR Metabolic score for insulin resistance; MetS Metabolic syndrome.

15 August 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
XZXiao-Jiao Zhang
Xiao-Jiao Zhang
XHXiao-Wei Han
Xiao-Wei Han
YJYan-Hui Jiang
Yan-Hui Jiang
YWYa-Le Wang
Ya-Le Wang
XHXing-Ling He
Xing-Ling He
ZYZhongqi Yang
Zhongqi Yang

19 September 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
PLPengpeng Liang
Pengpeng Liang
SZShizhao Zhang
Shizhao Zhang
MYMei Yan
Mei Yan
HHHai Huang
Hai Huang
JKJinhua Kang
Jinhua Kang
HWHongyan Wu
Hongyan Wu
Objective: To analyze trends in the global burden (GBD) of ischemic heart disease (IHD) over the past 30 years and health inequalities, as well as to predict the trends for the next 25 years.Methods: Data on the incidence, prevalence, mortality, Disability-Adjusted Life Years (DALYs), and risk factors for IHD were obtained from GBD 2021. Changing global, regional, and national trends from 1990 to 2021 were analyzed, accompanied by decomposition analysis. Potential for improvement was assessed using frontier analysis while conducting a regional risk factor ranking analysis. Joinpoint software and an age-period-cohort model were used to analyze IHD data further. Finally, future IHD trends were analyzed using the prediction models such as the Bayesian age-period-cohort analysis (BAPC) model.Results: According to GBD 2021, the global incidence of IHD cases was 31,872,778 (201.6%, compared to 1990), with 254,276,268 prevalent cases (226.7%, compared to 1990), 188,360,557 DALYs (158.1%, compared to 1990), and 8,991,637 deaths (167.5%, compared to 1990). Significant changes were noted in Uzbekistan, China, and Indonesia. Male patients outnumbered females, and most were over 60. In 2021, the total amount of IHD was primarily driven by ageing and population growth, with substantial potential for improvement observed in middle and high Socio-Demographic Index (SDI) regions; future attention should also be directed toward occupational risks, air quality, and renal dysfunction’s impact on IHD. The BAPC method showed that the incidence of IHD would reach 56,431,619 cases by 2046. This would be 1.77 times the number of cases in 2021.Conclusion: From 1990 to 2021, the number of IHD cases in the world and its forecast analysis showed an upward trend, mainly affected by population growth and aging. The disparity of medical burden in areas with low, middle and medium development levels is worsening. The importance of regional rankings of risk factors for IHD has also shifted due to global economic changes over the past 30 years. This study highlights the challenges faced in managing IHD and calls for governments and institutions to adopt multidimensional public health strategies encompassing age, risk factors, gender, and predictive models to address the growing number of cases and other health problems. These findings will guide health policies to effectively control clinical stress in IHD by prioritizing regional risk factors for targeted interventions and individualized prevention for high-risk populations, while also ensuring efficient use of health resources.

19 August 2014 in Journal of Asian Natural Products Research
Verified
Journal Article
Closed access
JGJing Gu
Jing Gu
HLHai-Long Li
Hai-Long Li
HWHongyan Wu
Hongyan Wu
MGMei Gu
Mei Gu
YLYingdong Li
Yingdong Li
KLKai Liu
Kai Liu
The main pathological change in radiation-induced heart disease is fibrosis. Emerging evidence has indicated that sodium tanshinone IIA sulfonate (STS) was used for treating fibrosis diseases. The present study was undertaken to characterize the effect of STS on radiation-induced cardiac fibrosis (RICF) on cultured cardiac fibroblasts (CFs). CFs were irradiated with 1 or 2 Gy X-rays, and the expression of TGF-β1 and collagen I (Col-1) increased, indicating that low-dose X-rays promoted fibrosis damage effect. The fibrosis damage was accompanied by morphologic changes in the endoplasmic reticulum (ER), as well as an increase in the expression of the ER stress-related molecules, GRP78 and CHOP. Administration of STS reduced ROS production and decreased the expression of Col-1, TGF-β1, p-Smad2/3, GRP78, and CHOP in irradiated CFs, thus weakening the radiation-induced fibrosis damage and ER stress. Radiation-induced fibrosis damage was observed on a cellular level. The involvement of ER stress in radiation-induced fibrosis damage was demonstrated for the first time. STS attenuated the fibrosis damage effect in CFs and this effect may be related to its antioxidant action, and also related to its inhibition of ER stress and TGF-β1-Smad pathway. These results suggest that STS shows a good prospect in clinical prevention and treatment of RICF.

28 August 2014 in Oncology Reports
Verified
Journal Article
Open access
PDF file
HLHailong Li
Hailong Li
SXShoupin Xie
Shoupin Xie
XLXiaojun Liu
Xiaojun Liu
HWHongyan Wu
Hongyan Wu
XLXinyao Lin
Xinyao Lin
YDYongqiang Duan
Yongqiang Duan
Matrine, a major alkaloid extracted from Sophora flavescens, has been reported to possess antitumor properties in several types of cancers, including gastric cancer. However, its mechanisms of action on gastric cancer remain poorly understood. Dysregulation of microRNAs, a class of small, non-coding, regulatory RNA molecules involved in gene expression, is strongly correlated with cancer. The aim of the present study was to demonstrate that matrine treatment altered miRNA expression in SGC7901 cells. Using miRCURY™ microarray analysis, we identified 128 miRNAs substantially exhibiting >2-fold expression changes in matrine-treated cells relative to their expression levels in untreated cells. RT-qPCR was used to show that the levels of 8 miRNAs whose target genes were clustered in the cell cycle pathway increased, while levels of 14 miRNAs whose target genes were clustered in the MAPK signaling pathway decreased. These results were consistent with those from the miRNA microarray experiment. Bioinformatical analysis revealed that the majority of 57 identified enrichment pathways were highly involved in tumorigenesis. In conclusion, the results demonstrated that matrine induces considerable changes in the miRNA expression profiles of SGC7901 cells, suggesting miRNA microarray combined with RT-qPCR validation and bioinformatical analysis provide a novel and promising approach to identify anticancer targets and the mechanisms of matrine involved.

24 September 2025 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
JLJiajun Liu
Jiajun Liu
JKJinhua Kang
Jinhua Kang
PLPengpeng Liang
Pengpeng Liang
ZSZhangxiao Song
Zhangxiao Song
GLGuiyun Li
Guiyun Li
HWHongyan Wu
Hongyan Wu
The triglyceride-glucose index (TyG) is an emerging marker of metabolic health, yet its association with mortality across different glucose metabolism statuses remains unclear. This study aimed to investigate the relationship between the TyG and the risk of all-cause and cardiovascular mortality among individuals with normoglycemia, dysglycemia, and diabetes mellitus. Participants from nine cycles of the National Health and Nutrition Examination Survey (NHANES) were included and categorized into three groups: normoglycemia, dysglycemia, and diabetes. Cox regression and restricted cubic spline (RCS) analyses were performed to evaluate the linear and nonlinear associations between TyG and mortality. To assess the predictive power of TyG and the atherogenic index of plasma (AIP) for mortality, time-dependent receiver operating characteristic (ROC) curves were constructed. Subgroup analyses were conducted based on age, sex, and blood pressure status. During a median follow-up of 9.2 years, a total of 2199 all-cause deaths and 606 cardiovascular deaths were documented. In the normoglycemic group, a single standard unit increase in TyG was associated with a 35% higher risk of all-cause mortality and a 38% higher risk of cardiovascular mortality (HR: 1.35, 95% CI 1.17–1.56; HR: 1.38, 95% CI 1.04–1.84, respectively). Among participants with diabetes, RCS analysis revealed a U-shaped association between TyG and all-cause/cardiovascular mortality, with an inflection point at 9.1. No significant associations were observed in the dysglycemia group. TyG demonstrated superior predictive performance compared to the AIP for 3-year mortality in both normoglycemic and diabetic individuals. Subgroup analyses identified significant interaction effects of age and sex on the association between TyG and mortality. TyG was associated with an increased risk of all-cause and cardiovascular death in the normoglycemic subgroup, but not in the dysglycemic subgroup. In the diabetes subgroup, the association between the TyG and mortality was nonlinear. The predictive value of TyG across different glucose metabolism statuses provides new evidence for medical practice. A total of 23,103 participants with normoglycemia (n=10,078), dysglycemia (n=8748), and diabetes (n=4277) were included. The median follow-up time was 9.2 years. Weighted COX regression results (upper), restricted cubic spline results (lower left), and time-dependent (cut-off value of 36 months) receiver operating characteristic curve results (lower right).TyG, triglyceride glucose index; AIP, atherogenic index of plasma; RCS, restricted cubic spline; ROC, receiver operating characteristic. *The results of the Cox regression used TyG as a continuous variable.